drugset / Trial / NCT03558334

Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia

NCT03558334

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, single-center, dose escalation study to evaluate of safety and efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in premature infants for moderate and severe Bronchopulmonary Dysplasia(BPD).

Timeline

Start
2018-06-28
Primary completion
2021-12-31
Completion
2022-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+06 cells/kg Intravenous